Skip to main content

Shields Matthew's Form 4 filing

Teva Pharmaceutical Industries Ltd (TEVA) · filed Jun 4, 2026

Accession no.
0001193125-26-257344
Filed
Jun 4, 2026
Trade date
Jun 3, 2026
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $532.3K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Shields MatthewCIK 0002025621Officer (EVP, Global Operations)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 3, 2026Ordinary SharesMOption exerciseAcquired+16,195–F2–26,184Direct
Jun 3, 2026Ordinary SharesSSaleDisposed−16,195$32.87−$532,329.659,989Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 3, 2026Ordinary SharesMOption exerciseDisposed−16,195$0.00$032,392Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)